a public good project by the
Synthesis
Company
of California

© 2026

Anthony P. Adamis | doi.page

0 works0 citations0 h-index

Anthony P. Adamis

Massachusetts Eye and Ear Infirmary(US)Harvard University(US)

Publications by Year

Research Areas

Retinal Diseases and Treatments, Glaucoma and retinal disorders, Retinal Imaging and Analysis, Angiogenesis and VEGF in Cancer, Retinal and Optic Conditions

Most-Cited Works

→ Pegaptanib for Neovascular Age-Related Macular Degeneration(2004)2,309 cited
→ Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease(2006)1,556 cited
→ A central role for inflammation in the pathogenesis of diabetic retinopathy(2004)1,163 cited
→ Ten years of anti-vascular endothelial growth factor therapy(2016)999 cited
→ Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies(2003)956 cited
→ Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials(2013)813 cited
→ Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

(1999)

786 cited

→ Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury(2007)705 cited

→ Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman Primate(1996)631 cited

→ A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema(2005)590 cited